Beyond Transposons: as a Pan-Cancer Biomarker and Immune Modulator.

: (Trigger Transposable Element Derived 1) is a recently identified oncogene with largely unexplored biological functions. Emerging evidence suggests its involvement in multiple cellular processes across cancer types. This study aimed to perform a comprehensive pan-cancer analysis of to evaluate its expression patterns, diagnostic utility, prognostic value, and association with immunotherapy response and drug resistance. : Transcriptomic and clinical data from TCGA and GTEx were analyzed using various bioinformatic tools. Expression profiling, survival analysis, immune correlation studies, gene set enrichment, single-cell sequencing, and drug sensitivity assessments were performed. : was found to be significantly upregulated in various tumor types, with notably high expression in colon adenocarcinoma. Elevated expression was associated with poor prognosis in several cancers. levels correlated with key features of the tumor immune microenvironment, including immune checkpoint gene expression, TMB, and MSI, suggesting a role in modulating anti-tumor immunity. GSEA and single-cell analyses implicated in oncogenic signaling pathways. Furthermore, high expression was linked to resistance to several therapeutic agents, including Zoledronate, Dasatinib, and BLU-667. : may serve as a promising diagnostic and prognostic biomarker, particularly in colon, gastric, liver, and lung cancers. Its strong associations with immune modulation and therapy resistance highlight its potential as a novel target for precision oncology and immunotherapeutic intervention.